NKGen Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Mar '24 Mar 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.08	0.43
Revenue Growth (YoY)	-	-	-81.92%	-
Cost of Revenue	-	-	0.02	0.03
Gross Profit	-	-	0.06	0.4
Selling, General & Admin	15.26	14.08	7.66	7.59
Research & Development	15.31	15.67	16.75	14.67
Operating Expenses	30.57	29.75	24.41	22.26
Operating Income	-30.57	-29.75	-24.35	-21.86
Interest Expense	-1.78	-0.75	-2.31	-1.32
Other Non Operating Income (Expenses)	-42.91	-48.18	0.08	-0.08
EBT Excluding Unusual Items	-75.26	-78.68	-26.57	-23.26
Merger & Restructuring Charges	-3.33	-3.33	-	-
Other Unusual Items	-1.42	-0.94	-0.18	-
Pretax Income	-80.01	-82.95	-26.75	-23.26
Income Tax Expense	0.01	0.01	0.01	0.01
Net Income	-80.01	-82.95	-26.75	-23.27
Net Income to Common	-80.01	-82.95	-26.75	-23.27
Shares Outstanding (Basic)	18	15	6	14
Shares Outstanding (Diluted)	18	15	6	14
Shares Change (YoY)	189.50%	142.70%	-55.39%	-
EPS (Basic)	-4.55	-5.38	-4.21	-1.63
EPS (Diluted)	-4.55	-5.38	-4.21	-1.63
Free Cash Flow	-21.07	-21.95	-22.66	-19.95
Free Cash Flow Per Share	-1.20	-1.42	-3.56	-1.40
Gross Margin	-	-	76.62%	92.96%
Operating Margin	-	-	-31618.18%	-5131.69%
Profit Margin	-	-	-34745.45%	-5461.27%
Free Cash Flow Margin	-	-	-29425.97%	-4683.33%
EBITDA	-29.38	-28.54	-23.14	-20.73
D&A For EBITDA	1.19	1.2	1.21	1.13
EBIT	-30.57	-29.75	-24.35	-21.86

Source: S&P Capital IQ. Standard template. Financial Sources.